Oluwagbenga Oguntoye Oluwatosin, Lukman Olaitan Abdulkareem, Ihiovi Umoru Benedict, Gideon Osasona Oluwadamilola, Maryjoy Ifeorah Ijeoma, Elijah Ariyo Olumuyiwa, Samson Jegede Oluwatosin, Adenike Oguntoye Oluwafunmilayo
Department of Medicine, Afe Babalola University Ado-Ekiti, Ado-Ekiti, Ekiti State, Nigeria.
Department of Medicine, Federal Teaching Hospital Ido-Ekiti, Ido-Ekiti, Ekiti State, Nigeria.
SAGE Open Med. 2024 Aug 7;12:20503121241264313. doi: 10.1177/20503121241264313. eCollection 2024.
This study aimed to assess hepatic fibrosis, using noninvasive tests, among patients with chronic hepatitis B virus infection in Nigeria.
The study was a retrospective cross-sectional, hospital-based, multicentered study. The data of adult Nigerians who were aged 18 years and above who had been diagnosed with chronic hepatitis B infection and were not on treatment were extracted from three tertiary health institutions across Nigeria. Sociodemographic and relevant clinical data were obtained from the case notes of the patients. Fibrosis-4 and aspartate aminotransferase platelet ratio index scores were calculated to determine the presence and severity of liver fibrosis in the patients. The data obtained were analyzed using Statistical Package for the Social Sciences (version 25.0). A -value of less than 0.05 was considered as statistically significant.
The data of a total of 234 patients were extracted for this study from across 3 tertiary hospitals in Nigeria. There were 132 (56.4%) males and 102 (43.6%) females in a ratio of 1.29:1 with a mean age of 37.92 ± 12.34 years. The fibrosis-4 score of the patients showed that 62.8% had "Normal/Mild Fibrosis," 25.6% had "Moderate Fibrosis," and 11.5% had "Severe Fibrosis/Cirrhosis." The aspartate aminotransferase platelet ratio index score of the patients showed that 64.1% had "No Fibrosis," 20.9% had "Mild Fibrosis," 6.4% had "Moderate Fibrosis," and 8.5% had "Severe Fibrosis/Cirrhosis." The median fibrosis-4 score of the patients was 1.18 (0.77-1.74), while the median aspartate aminotransferase platelet ratio index score was 0.40 (0.26-0.69). Liver ultrasonography detected cirrhosis in 8.5% of the patients. All the patients were not yet on treatment for hepatitis B infection.
The prevalence of hepatic fibrosis is high among patients with chronic hepatitis B virus infection in Nigeria and a large number of these patients were not yet on therapy. Noninvasive assessment of hepatic fibrosis should be considered as a critical part of the work-up of patients with chronic hepatitis B infection.
本研究旨在利用非侵入性检测方法评估尼日利亚慢性乙型肝炎病毒感染患者的肝纤维化情况。
本研究为一项基于医院的回顾性横断面多中心研究。从尼日利亚各地的三家三级医疗机构提取了年龄在18岁及以上、被诊断为慢性乙型肝炎感染且未接受治疗的成年尼日利亚人的数据。从患者的病历中获取社会人口统计学和相关临床数据。计算纤维化-4和天冬氨酸转氨酶-血小板比率指数得分，以确定患者肝纤维化的存在和严重程度。使用社会科学统计软件包（版本25.0）对获得的数据进行分析。P值小于0.05被认为具有统计学意义。
本研究从尼日利亚的3家三级医院共提取了234例患者的数据。其中男性132例（56.4%），女性102例（43.6%），男女比例为1.29:1，平均年龄为37.92±12.34岁。患者的纤维化-4得分显示，62.8%的患者为“正常/轻度纤维化”，25.6%的患者为“中度纤维化”，11.5%的患者为“重度纤维化/肝硬化”。患者的天冬氨酸转氨酶-血小板比率指数得分显示，64.1%的患者为“无纤维化”，20.9%的患者为“轻度纤维化”，6.4%的患者为“中度纤维化”，8.5%的患者为“重度纤维化/肝硬化”。患者的纤维化-4得分中位数为1.18（0.77 - 1.74），而天冬氨酸转氨酶-血小板比率指数得分中位数为0.40（0.26 - 0.69）。肝脏超声检查发现8.5%的患者患有肝硬化。所有患者尚未接受乙型肝炎感染治疗。
尼日利亚慢性乙型肝炎病毒感染患者中肝纤维化的患病率较高，且这些患者中有大量尚未接受治疗。肝纤维化的非侵入性评估应被视为慢性乙型肝炎感染患者检查工作的重要组成部分。
